High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: Complete remission at transplantation is the major determinant of outcome - Lymphoma working party of the European group for blood and marrow transplantation

被引:108
|
作者
Kyriakou, Charalampia
Canals, Carmen
Goldstone, Anthony
Caballero, Dolores
Metzner, Bernd
Kobbe, Guido
Kolb, Hans-Jochem
Kienast, Joachim
Reimer, Peter
Finke, Jurgen
Oberg, Gunnar
Hunter, Ann
Theorin, Niklas
Sureda, Anna
Schmitz, Norbert
机构
[1] UCL, Northwood HA6 3NG, Middx, England
[2] European Bone Marrow Transplantat Grp, London, England
[3] Leicester Royal Infirm, Leicester, Leics, England
[4] Hosp Clin Serv Hematol, Salamanca, Spain
[5] Hosp Santa Creu & Sant Pau, E-08025 Barcelona, Spain
[6] Univ Hosp, Dept Med, Uppsala, Sweden
[7] Univ Freiburg, Dept Med Hematol Oncol, D-7800 Freiburg, Germany
[8] Univ Wurzburg, Med Klin, D-8700 Wurzburg, Germany
[9] Univ Munster, Dept Hematol Oncol, Munster, Germany
[10] Univ Munich, Klinikum Grosshadern, D-8000 Munich, Germany
[11] Univ Dusseldorf, Dusseldorf, Germany
[12] Klin Oldenburg, Hamatol Onkol Abt, Oldenburg, Germany
关键词
D O I
10.1200/JCO.2007.12.6219
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Patients with angioimmunoblastic T-cell lymphoma (AITL) have poor prognoses with current conventional chemotherapy. The aim of this study was to evaluate the effect of high-dose therapy (HDT) followed by autologous stem-cell transplantation (ASCT) on patients with AITL. Patients and Methods We report a retrospective, multicenter study of 146 patients with AITL who received ASCT. The source of the stem cells was peripheral blood in 143 patients. The conditioning regimen varied, and 74% of the patients received carmustine and 1,3-bis(2-chloroethyl)-1-nitrosourea; etoposide; ara-C; and melphalan chemotherapy. Results After a median follow-up of 31 months (range, 3 to 174 months), 95 patients (65%) remained alive, and 51 patients (35%) died. Forty-two patients died as a result of disease progression, and nine died as a result of regimen-related toxicity. The cumulative incidence of nonrelapse mortality was 5% and 7% at 12 and 24 months, respectively. The actuarial overall survival (OS) was 67% at 24 months and 59% at 48 months. The cumulative incidence of relapse was estimated at 40% and 51% at 24 and 48 months, respectively. Disease status at transplantation was the major factor that impacted outcome. Patients who received a transplant during first complete remission (CR) had significantly superior progression-free survival and OS. The estimated PFS rates for patients who received their transplants in CR were 70% and 56% at 24 and 48 months, respectively; 42% and 30% for patients with chemotherapy-sensitive disease at those time points, respectively; and 23% at both time points for patients with chemotherapy- refractory disease. Conclusion This study shows that HDT and ASCT offers the possibility of long-term disease-free survival to patients with AITL. Early transplantation is necessary to achieve optimal results.
引用
收藏
页码:218 / 224
页数:7
相关论文
共 50 条
  • [31] The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission:: the Spanish Lymphoma and Autologous Transplantation Group experience
    Rodriguez, J.
    Conde, E.
    Gutierrez, A.
    Arranz, R.
    Leon, A.
    Marin, J.
    Bendandi, M.
    Albo, C.
    Caballero, M. D.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 (04) : 652 - 657
  • [32] High-dose therapy and stem cell transplantation in follicular lymphoma
    J. W. Friedberg
    A. S. Freedman
    [J]. Annals of Hematology, 1999, 78 : 203 - 211
  • [33] Hematopoietic stem cell transplantation in patients with Lymphomatoid Granulomatosis (LG): A survey of the lymphoma working party of the European Group for Blood and Marrow Transplantation (EBMT)
    Siegloch, K.
    Schmitz, N.
    Friedrichs, B.
    Hamilton, E.
    Harrison, B.
    van Imhoff, G. W.
    Montoto, S.
    Holler, E.
    Ribera, J. M.
    Delage, R.
    Duehrsen, U.
    Luan, J. -J.
    Dreger, P.
    Sureda, A.
    [J]. ONKOLOGIE, 2012, 35 : 247 - 247
  • [34] High-dose therapy and autologous peripheral blood stem cell transplantation for HIV-associated lymphoma
    Re, A
    Cattaneo, C
    Casari, S
    Spina, M
    Michieli, M
    Rupolo, M
    Nosari, A
    Ferremi, P
    Lanfranchi, A
    Mazzuccato, M
    Abruzzese, L
    Tirelli, U
    Carosi, G
    Rossi, G
    [J]. BONE MARROW TRANSPLANTATION, 2003, 31 : S71 - S71
  • [35] HIGH-DOSE THERAPY AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR ADULT PATIENTS WITH LYMPHOBLASTIC LYMPHOMA - RESULTS OF THE EUROPEAN GROUP FOR BONE-MARROW TRANSPLANTATION
    SWEETENHAM, W
    LIBERTI, G
    PEARCE, R
    TAGHIPOUR, G
    SANTINI, G
    GOLDSTONE, AH
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (07) : 1358 - 1365
  • [36] Allogeneic stem cell transplantation in angioummunoblastic T-cell lymphoma: a retrospective survey from the Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT)
    Kyriakou, C
    Canals, C
    Taghipour, G
    Finke, J
    Kolb, HJ
    Goldstone, AH
    Sureda, A
    Schmitz, N
    [J]. BONE MARROW TRANSPLANTATION, 2006, 37 : S27 - S27
  • [37] High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission
    Freedman, AS
    Gribben, JG
    Neuberg, D
    Mauch, P
    Soiffer, RJ
    Anderson, KC
    Pandite, L
    Robertson, MJ
    Kroon, M
    Ritz, J
    Nadler, LM
    [J]. BLOOD, 1996, 88 (07) : 2780 - 2786
  • [38] Autologous Hematopoietic Stem Cell Transplantation for Plasmablastic Lymphoma: The European Society for Blood and Marrow Transplantation Experience
    Cattaneo, Chiara
    Finel, Herve
    McQuaker, Grant
    Vandenberghe, Elizabeth
    Rossi, Giuseppe
    Dreger, Peter
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (06) : 1146 - 1147
  • [39] Second Autologous Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma after a Previous Autograft: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
    Martinez, Carmen
    Boumendil, Ariane
    Romejko-Jarosinska, Joanna
    Anagnostopoulos, Achilles
    Faber, Edgar
    Poire, Xavier
    Yakoub-Agha, Ibrahim
    Akhtar, Saad
    Gurman, Gunhan
    Pavone, Vincenzo
    Halaburda, Kazimierz
    Sousa, Aida Botelho
    Ghesquieres, Herv
    Finel, Herve
    Khvedelidze, Irma
    Montoto, Silvia
    Sureda, Anna
    [J]. BLOOD, 2018, 132
  • [40] Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)
    Dietrich, S.
    Boumendil, A.
    Finel, H.
    Avivi, I.
    Volin, L.
    Cornelissen, J.
    Jarosinska, R. J.
    Schmid, C.
    Finke, J.
    Stevens, W. B. C.
    Schouten, H. C.
    Kaufmann, M.
    Sebban, C.
    Trneny, M.
    Kobbe, G.
    Fornecker, L. M.
    Schetelig, J.
    Kanfer, E.
    Heinicke, T.
    Pfreundschuh, M.
    Diez-Martin, J. L.
    Bordessoule, D.
    Robinson, S.
    Dreger, P.
    [J]. ANNALS OF ONCOLOGY, 2014, 25 (05) : 1053 - 1058